PMID- 24337717
OWN - NLM
STAT- MEDLINE
DCOM- 20140516
LR  - 20220321
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 22
IP  - 3
DP  - 2014 Mar
TI  - Prevention and management of adverse events related to regorafenib.
PG  - 837-46
LID - 10.1007/s00520-013-2085-z [doi]
AB  - Regorafenib is an oral multikinase inhibitor that has shown antitumor activity in 
      a range of solid tumors. Based on data from phase III clinical trials, 
      regorafenib is indicated for the treatment of adult patients with metastatic 
      colorectal cancer who have previously been treated with, or are not considered 
      candidates for, other available therapies, and in patients with advanced 
      gastrointestinal stromal tumors that cannot be surgically removed and no longer 
      respond to other appropriate treatments. A panel of oncology nurses, research 
      coordinators, and other medical oncology experts, experienced in the care of 
      patients treated with regorafenib, met to discuss the best practice for the 
      management of regorafenib-associated adverse events (AEs). The panel agreed that, 
      in clinical trials and daily practice with regorafenib, AEs are common but mostly 
      manageable. The most common and/or important AEs associated with regorafenib were 
      considered to be hand-foot skin reaction, rash or desquamation, stomatitis, 
      diarrhea, hypertension, liver abnormalities, and fatigue. This manuscript 
      describes the experience and recommendations of the panel for managing these AEs 
      in everyday clinical practice. Appropriate education, monitoring, and management 
      are considered essential for reducing the incidence, duration, and severity of 
      regorafenib-associated AEs.
FAU - De Wit, Mieke
AU  - De Wit M
AD  - Digestive Oncology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, 
      Belgium, mieke.1.dewit@uzleuven.be.
FAU - Boers-Doets, Christine B
AU  - Boers-Doets CB
FAU - Saettini, Alessandra
AU  - Saettini A
FAU - Vermeersch, Kristina
AU  - Vermeersch K
FAU - de Juan, Carmen Roncero
AU  - de Juan CR
FAU - Ouwerkerk, Jan
AU  - Ouwerkerk J
FAU - Raynard, See-See
AU  - Raynard SS
FAU - Bazin, Ashley
AU  - Bazin A
FAU - Cremolini, Chiara
AU  - Cremolini C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20131214
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 24T2A1DOYB (regorafenib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Colorectal Neoplasms/drug therapy
MH  - Exanthema/chemically induced/prevention & control
MH  - Fatigue/chemically induced/prevention & control
MH  - Foot/pathology
MH  - Gastrointestinal Stromal Tumors/drug therapy
MH  - Hand/pathology
MH  - Humans
MH  - Hypertension/chemically induced/prevention & control
MH  - Phenylurea Compounds/*adverse effects/therapeutic use
MH  - Pyridines/*adverse effects/therapeutic use
PMC - PMC3913844
EDAT- 2013/12/18 06:00
MHDA- 2014/05/17 06:00
PMCR- 2013/12/14
CRDT- 2013/12/17 06:00
PHST- 2013/09/25 00:00 [received]
PHST- 2013/11/26 00:00 [accepted]
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/05/17 06:00 [medline]
PHST- 2013/12/14 00:00 [pmc-release]
AID - 2085 [pii]
AID - 10.1007/s00520-013-2085-z [doi]
PST - ppublish
SO  - Support Care Cancer. 2014 Mar;22(3):837-46. doi: 10.1007/s00520-013-2085-z. Epub 
      2013 Dec 14.